Pharmally sweetheart deal warrants probe | Inquirer Opinion

Pharmally sweetheart deal warrants probe

/ 04:02 AM September 27, 2021

Congressmen said the Senate blue ribbon committee’s investigation of the transfer of COVID-19 funds from the Department of Health to the Department of Budget and Management is meant to destroy the President.

Far from it. The President himself said he requested Michael Yang, a Chinese national and a long-time Davao businessman, to help Pharmally Pharmaceutical Corp., a newly organized trading company with a capital of only P625,000 and with no track record. The award of the P8.7 billion contract to Pharmally is a sweetheart deal. One who has P42 billion will not even think of talking to a new entity with only P625,000 capital, no declared income, and no track record.


The award to Pharmally is grossly disadvantageous to the government; it calls for a thorough investigation for violation of the Anti-Graft and Corrupt Practices Act.

In a similar situation, Malacañang would say: “If they have nothing to hide, they should let the hearings continue.”


Jose J. Ferrer, Jr., [email protected]

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, DBM, Pharmally
For feedback, complaints, or inquiries, contact us.

Fearless views on the news

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.

© Copyright 1997-2022 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.